Trump's Executive Order Ignites Biotech Surge as Psychedelic Research Gains Momentum
In a dramatic market move, three biotech stocks experienced a wild surge on Monday, driven by President Donald Trump's executive action aimed at facilitating access to psychedelic drugs for medical research. Investors flocked to the niche biotech sector, propelling shares sharply higher across the board, signaling a significant shift in regulatory attitudes toward once-taboo therapies.
Stock Performance Highlights
Definium Therapeutics saw its shares climb 10 percent at the market open, while AtaiBeckley surged nearly 30 percent. The standout performer was Compass Pathways, which skyrocketed an impressive 60 percent. This rally followed Trump's signing of an executive order on Saturday, designed to accelerate the development of new treatments for conditions such as depression and post-traumatic stress disorder (PTSD).
Executive Order Details and Federal Support
The order directs the Food and Drug Administration (FDA) to prioritize certain psychedelic drugs and establish a streamlined pathway for patient access. Additionally, it allocates federal funding for research, marking one of the strongest indications yet that Washington is warming to these alternative therapies. Proponents argue that compounds like psilocybin—the active ingredient in magic mushrooms—could revolutionize mental health treatment.
Influential Backers and Advocacy
The high-profile announcement was inspired by the efforts of Health Secretary Robert F. Kennedy Jr., who has long championed psychedelic drugs as viable treatments for mental health issues. Over the past decade, podcast host Joe Rogan has been a vocal advocate, hosting scientists and researchers to shift public perception of psychedelics from counter-culture symbols to legitimate mental health aids. Kennedy has integrated this advocacy into his "make America healthy again" (MAHA) mission, criticizing the FDA for historically suppressing psychedelic research in favor of conventional treatments like SSRIs.
Wall Street Analysis and Company Focus
Wall Street is increasingly embracing this shift. Deutsche Bank noted that several psychedelic companies have emerged as bona fide drug developers, attracting attention from healthcare and biotech investors. RBC Capital Markets analyst Brian Abrahams cautioned that while Trump's order does not explicitly recommend psychedelic drugs, it suggests drug developers will benefit from "diminishing regulatory risk."
- Compass Pathways is solely focused on developing a high-purity version of psilocybin, with its drug candidate in advanced trials for treatment-resistant depression. Recent trial data showed that a single dose, combined with therapy, led to a rapid and lasting reduction in depression symptoms.
- AtaiBeckley is working on two drug candidates, BPL-003 and VLS-01, for treatment-resistant depression. The company aims to create products with shorter durations—around two hours—making them more manageable for clinical use compared to traditional six- to eight-hour trips.
This regulatory shift underscores a growing acceptance of psychedelic therapies, potentially transforming mental health care and opening new investment opportunities in the biotech sector.
